September 21, 2023

Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting

August 08, 2023

ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS

June 12, 2023

Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe

April 03, 2023

Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension

August 16, 2022

Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation

August 09, 2022

New Drug Filing for Cenobamate Accepted for Review in Canada and Israel

August 09, 2022

ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS

August 08, 2022

Paladin Labs Announces Health Canada's Filing Acceptance of Cenobamate Tablets as an Adjunctive Therapy for the Management of Partial-Onset Seizures in Adults with Epilepsy

July 15, 2022

Endo Announces Agreement for Paladin Labs to Develop, Commercialize and Supply Quoin Pharmaceuticals' QRX003 in Canada

July 01, 2022

Opana® ER Antitrust Trial Concludes With Jury Verdict in Endo's Favor

July 01, 2022

Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants with Adhesive Capsulitis of the Shoulder

June 13, 2022

Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain

June 09, 2022

National Survey of Over 1,500 Men Shows More Than Half Were Unsure of How to Improve Their Mental and Sexual Health; New Partnership Aims to Change That Through Education and Free Virtual Consultations

May 05, 2022

ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS

May 05, 2022

Endo Aesthetics to Introduce New Clinical Study of Qwo® (collagenase clostridium histolyticum-aaes) at the Annual SCALE Meeting

May 02, 2022

Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar

April 20, 2022

Tennessee Court of Appeals Orders Recusal of Trial Court Judge and Vacates Default Judgment on Liability Against Endo

April 12, 2022

Endo to Announce First-Quarter 2022 Financial Results

March 28, 2022

Endo Begins Shipment of Premixed Ephedrine Sulfate Injection in Ready-to-Use Vials

March 03, 2022

Endo Launches New Living Our Values Program to Recognize Outstanding Team Members

March 02, 2022

Butt First: Endo Launches First Direct-to-Consumer Campaign for Qwo® (collagenase clostridium histolyticum-aaes) With 200+ Patient Events

February 28, 2022

ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS

February 11, 2022

Endo Comments on Default Judgment on Liability in Tennessee State Court

February 07, 2022

Endo Announces Launch of Ready-to-Use VASOSTRICT® (vasopressin injection, USP) in Pre-Mix Bottles

January 25, 2022

Endo to Announce Fourth Quarter and Full-Year 2021 Financial Results

January 18, 2022

Endo Reaches Agreement Intended to Settle Florida Governmental Opioid Cases and Claims

January 17, 2022

Paladin Labs Announces the Launch of Xydalba® (dalbavancin for injection) in Canada

January 13, 2022

Endo Announces Publication of New AVEED® (testosterone undecanoate) Data in Peer-Reviewed Journal of Clinical Pharmacology; Data Evaluates Dosing Flexibility in Men With Hypogonadism

January 11, 2022

Endo Appoints Dr. James P. Tursi as Executive Vice President, Global Research & Development

January 10, 2022

Endo Launches New Dupuytren's Contracture Campaign Featuring Real Patients: Watching Education Unfold

January 04, 2022

Endo Launches First Generic Version of CUVPOSA® (glycopyrrolate) Oral Solution

January 04, 2022

Endo to Participate at J.P. Morgan 40th Annual Healthcare Conference

December 23, 2021

Endo Reaches Agreement Intended to Settle Texas Governmental Opioid Cases and Claims

December 23, 2021

Endo Announces Agreement for Paladin Labs to Commercialize SK Biopharmaceuticals' XCOPRI® (Cenobamate) in Canada

December 15, 2021

Endo Announces Favorable Final Ruling in California State Court Opioid Trial

November 22, 2021

Endo's Qwo® (collagenase clostridium histolyticum-aaes) Data Presented at the American Society for Dermatologic Surgery's Annual Meeting

November 18, 2021

Endo Begins Shipment of Generic MIACALCIN® (calcitonin salmon) Injection

November 17, 2021

Endo Announces Fill-Finish Manufacturing Agreement with U.S. Government to Support Production of Critical Medicines

November 08, 2021

Endo Announces Agreement with Premier to Supply VASOSTRICT® (vasopressin injection, USP) Vials, Essential for COVID-19 Care

November 04, 2021

Endo Reports Third-Quarter 2021 Financial Results And Raises 2021 Financial Guidance

November 02, 2021

California State Court Issues Tentative Ruling in Endo's Favor Following Opioid Trial

October 25, 2021

Endo Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease

October 22, 2021

Endo Presents New XIAFLEX® (collagenase clostridium histolyticum) Data Analysis at Sexual Medicine Society of North America (SMSNA) Annual Meeting

October 05, 2021

Endo to Announce Third Quarter 2021 Financial Results

September 30, 2021

Endo Presents New Investigational Collagenase Clostridium Histolyticum (CCH) Survey Data at American Society for Surgery of the Hand (ASSH) Annual Meeting

September 28, 2021

Endo Reaches Agreement in Principle to Settle Louisiana Governmental Opioid Cases and Claims

September 22, 2021

Endo Launches First and Only Generic Version of Chantix® (varenicline) Tablets in the United States

September 09, 2021

Endo Settles New York State Opioid Cases and Provides Update on Remaining Opioid Litigation

August 31, 2021

Endo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation

August 05, 2021

Endo Reports Second-Quarter 2021 Financial Results And Updates 2021 Financial Guidance